This legislation aims to create a specific regulatory framework for homeopathic drug products within the Federal Food, Drug, and Cosmetic Act. Its primary purpose is to ensure continued consumer and practitioner access to these products by establishing clear standards for their safety, quality, and transparency, while preventing unreasonable regulatory barriers. The bill defines a homeopathic drug product as one containing only homeopathic ingredients, which are listed in recognized pharmacopoeias or prepared according to specific safety and quality standards. It significantly limits the applicability of existing drug regulations, stating that only sections concerning adulteration, misbranding, and registration apply, provided they do not conflict with the new provisions or homeopathic standards. For adulteration , homeopathic products must comply with safety and quality standards from the Homeopathic Pharmacopoeia or accredited voluntary consensus standards. Manufacturers can petition for exemptions or variances from good manufacturing practice (GMP) regulations, with automatic approval if the Secretary does not decide within 180 days, provided product safety is not compromised. While finished products are exempt from active ingredient identity and strength testing, intermediate testing is required for starting materials posing a substantial risk, ensuring they do not exceed a defined safe level. Regarding misbranding , the bill mandates specific labeling requirements for homeopathic products, including expressing dosages as attenuations (e.g., "3x" or "6c"). Retail products must include purposes or indications for self-limiting conditions, supported by various sources such as traditional references, scientific evidence, or real-world data, alongside a disclaimer stating, "These indications have not been evaluated by the Food and Drug Administration. This product is intended for traditional homeopathic uses." The legislation offers significant protections by stipulating that compliant labeling and marketing claims are not considered false advertising under the Federal Trade Commission Act, nor are they subject to other Federal or State substantiation requirements. It also prohibits private rights of action for false advertising based solely on the lack of clinical trials for homeopathic indications, and explicitly prohibits the Secretary from requiring premarket approval for these products. A key provision is the establishment of a Homeopathic Drug Product Advisory Committee , composed of diverse stakeholders, to advise on regulation and investigate adverse events. The bill also ensures federal inspectors are knowledgeable about these specific requirements, affirms it does not preempt state laws concerning homeopathy, and withdraws the FDA's December 2022 guidance on homeopathic drug products.